A Randomized Trial Comparing Colchicine and Ursodeoxycholic Acid Combination to Ursodeoxycholic Acid in Primary Biliary Cirrhosis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The efficacy of colchicine combined with ursodeoxycholic acid (UDCA) and UDCA alone in the treatment of patients with nonadvanced primary biliary cirrhosis (PBC) was evaluated in a 2–year controlled study. Seventy–four patients with PBC who had been treated previously with UDCA (at least 8 months) but still had abnormal liver test results, especially elevated alkaline phosphatase activity, were randomized to be administered colchicine (1 mg/d, 5 days per week) (n = 37) or a placebo (n = 37). In addition, the patients were treated with UDCA (13–15 mg · kg–1 · day–1). The patients underwent clinical examination and liver tests every 6 months and upper endoscopy and liver biopsy at entry and at 2 years. Procollagen type III aminoterminal peptide (PIIINP), hyaluronic acid, and sulfobromophthalein (BSP) elimination kinetics were determined at entry and after 2 years. After 2 years of treatment, relative to UDCA, colchicine combined with UDCA did not significantly improve symptoms, laboratory findings (serum bilirubin level, alkaline phosphatase and alanine transaminase [ALT] activities, immunoglobulin [Ig] M level), serum markers of fibrosis, or histological features, except lobular inflammation. Colchicine did tend to slightly reduce the progression of esophageal varices; however, the difference was not significant. BSP elimination kinetics (45–minute retention percentage) was significantly improved when treated with colchicine. During the 2–year study, the only clinical complications were variceal bleeding in one patient administered colchicine and two administered the placebo. Two patients died from nonliver causes. One severe adverse effect (peripheral neuromyopathy) was observed in a colchicine–treated patient. In conclusion, this study suggests that colchicine appears to provide a slight advantage relative to UDCA alone in patients with nonadvanced PBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Randomized trial of chlorambucil for primary biliary cirrhosis
Hoofnagle, J. H., Davis, G. L., Schafer, D. F., Peters, M., Avigan, M. I., Pappas, S. C., Hanson, R. G., Minuk, G. Y., Dusheiko, G. M., Campbell, G., et al. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90183-6 · Cited by 157 · cited 3×
“BSP elimi- rubin, alkaline phosphatase, alanine transaminase (ALT),nation kinetics (45-minute retention percentage) was and type III procollagen peptide levels, and tends to slowsignificantly improved when treated with colchicine. the histological progression of PBC22-24; (3) drug toxicity isDuring the 2-year study, t…”
Background
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“Anti-fibrotic agents Colchicine was inferior to UDCA in the treatment of PBC [42] and did not, when combined with UDCA in comparison to UDCA alone [43], significantly improve symptoms, serum liver tests, serum markers of fibrosis, or histological features.”
Result(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’
Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00092-7 · Cited by 411
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis
Corpechot, C., Carrat, F., Bahr, A., Chrétien, Y., Poupon, R.-E., & Poupon, R. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.009 · Cited by 390
Self-citation
Metadata
- Authors
- Poupon, R. E., Huet, P. M., Poupon, R., Bonnand, A., Van Nhieu, J. T., & Zafrani, E. S.
- Venue
- Hepatology
- Published
- 1996-11
- Volume
- 24
- Issue
- 5
- Pages
- 1098-1103
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2013190926
- Cited by
- 90
- References
- 5
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Trial Comparing Colchicine and Ursodeoxycholic Acid Combination to Ursodeoxycholic Acid in Primary Biliary Cirrhosis. https://app.cochat.ai/papers/10.1002/hep.510240520
- The paper
- Poupon, R. E., Huet, P. M., Poupon, R., Bonnand, A., Van Nhieu, J. T., & Zafrani, E. S. (1996). A Randomized Trial Comparing Colchicine and Ursodeoxycholic Acid Combination to Ursodeoxycholic Acid in Primary Biliary Cirrhosis. Hepatology. https://doi.org/10.1002/hep.510240520
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.